Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | Overview of a Phase II clinical trial of isatuximab

Joseph Mikhael • 29 Jan 2016
ASH 2015
Multiple Myeloma Isatuximab

Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of isatuximab (SAR650984) for the treatment of relapsed/refractory multiple myeloma (MM). Isatuximab is an anti-CD38 monoclonal antibody, that is very well tolerated by MM patients, with a response rate of 20-29% based on different cohorts. This drug is now being taken into a larger Phase II trial with over 100 patients taking one single dose of isatuximab.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

More from Joseph Mikhael

2:10
IKEMA trial update: Isatuximab in MM
Joseph Mikhael • 21 Oct 2020
1:53
Transplantation for consolidation in multiple myeloma
Joseph Mikhael • 21 Oct 2020
3:08
Disparities between African American and Caucasian patients with MM
Joseph Mikhael • 21 Oct 2020
2:10
Mentorship in the virtual era
Joseph Mikhael • 21 Oct 2020

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals